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ABSTRACT
OBJECTIVES
To compare the use of hormone therapy between 
Finnish postmenopausal women with and without a 




Finnish national population and drug register, 
between 1999 and 2013.
PARTICIPANTS
All postmenopausal women (n=84 739) in Finland 
who, between 1999 and 2013, received a diagnosis of 
Alzheimer’s disease from a neurologist or geriatrician, 
and who were identified from a national drug register. 
Control women without a diagnosis (n=84 739), 
matched by age and hospital district, were traced from 
the Finnish national population register.
INTERVENTIONS
Data on hormone therapy use were obtained from the 
Finnish national drug reimbursement register.
MAIN OUTCOME MEASURES
Odds ratios and 95% confidence intervals for 
Alzheimer’s disease, calculated with conditional 
logistic regression analysis.
RESULTS
In 83 688 (98.8%) women, a diagnosis for Alzheimer’s 
disease was made at the age of 60 years or older, and 
47 239 (55.7%) women had been over 80 years of age 
at diagnosis. Use of systemic hormone therapy was 
associated with a 9-17% increased risk of Alzheimer’s 
disease. The risk of the disease did not differ 
significantly between users of estradiol only (odds 
ratio 1.09, 95% confidence interval 1.05 to 1.14) and 
those of oestrogen-progestogen (1.17, 1.13 to 1.21). 
The risk increases in users of oestrogen-progestogen 
therapy were not related to different progestogens 
(noreth isterone acetate, medroxyprogesterone 
acetate, or other progestogens); but in women 
younger than 60 at hormone therapy initiation, 
these risk increases were associated with hormone 
therapy exposure over 10 years. Furthermore, the 
age at initiation of systemic hormone therapy was 
not a decisive determinant for the increase in risk 
of Alzheimer’s disease. The exclusive use of vaginal 
estradiol did not affect the risk of the disease (0.99, 
0.96 to 1.01).
CONCLUSIONS
Long term use of systemic hormone therapy might 
be accompanied with an overall increased risk of 
Alzheimer’s disease, which is not related to the type 
of progestogen or the age at initiation of systemic 
hormone therapy. By contrast, use of vaginal estradiol 
shows no such risk. Even though the absolute risk 
increase for Alzheimer’s disease is small, our data 
should be implemented into information for present 
and future users of hormone therapy.
Introduction
Alzheimer’s disease, the most common cause of 
dementia, occurs more frequently in women than in 
men.1 This difference might be due to the longer life 
expectancy of women, but sex specific differences in 
the incidence of Alzheimer’s disease might also exist.1-3 
It is known that oestrogens exert neuroprotection in 
several animal studies.4-6 Also, oestrogen deficiency as 
a result of early menopause has been associated with 
an increased risk of Alzheimer’s disease.7 Therefore, 
prolonging the oestrogen supply with postmenopausal 
hormone therapy could protect against Alzheimer’s 
disease. 
However, clinical data on the association between 
hormone therapy and the disease have remained 
inconclusive. Despite several observational studies 
supporting the protective effect of hormone therapy 
on Alzheimer’s disease,8-13 a subsequent placebo 
controlled trial (the Women’s Health Initiative Memory 
Study (WHIMS)) failed to confirm this benefit, and 
in fact implied an increased risk of overall dementia 
in hormone therapy users.14 15 The conflicting data 
could in part result from differences in the study 
design, study populations, or hormone therapy 
regimens. Unlike clinical practice, hormone therapy 
in the WHIMS trial was initiated in women aged 65 
or older.14 15 Thus, one explanation might also be the 
timing hypothesis, which suggests that oestrogen 
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could be neuroprotective only if started soon after the 
onset of menopause.16 This hypothesis originates from 
cardiovascular studies17 where the age at the start of 
hormone therapy appears to predict the cardiovascular 
effects of hormone therapy. Treatment initiated before 
age 60 is protective, but if started at a later age, it is 
detrimental towards the vasculature. Such a window 
for hormone therapy use has also been suggested for 
cognitive effects.16
By using Finnish comprehensive nationwide 
registers, we were able to conduct a case-control 
comparison to investigate whether hormone therapy 
had an effect on the risk of Alzheimer’s disease, and 
whether this risk was associated with age of treatment 
initiation or duration of treatment use.
Methods
In Finland, patients with Alzheimer’s disease 
are entitled to 40% reimbursement for treatment 
from national health insurance, but this requires a 
statement from a neurologist or geriatrician. They must 
base the diagnosis on symptoms consistent of mild 
or moderate Alzheimer’s disease, decrease in social 
capacity for at least three months, cognitive tests, 
magnetic resonance imaging or computed tomography 
scanning of the brain, and exclusion of alternative 
diagnoses. The physician also must confirm whether 
the patient has other dementia related diseases, such 
as Lewy body dementia or mixed dementia. For mixed 
dementia, patients are entitled to reimbursement only 
if the symptoms and findings are caused mainly by 
Alzheimer’s disease. In total, 84 739 women with a 
diagnosis for Alzheimer’s disease were entered into this 
register in 1999-2013. During the same period of time, 
control women without a diagnosis were identified 
from the Finnish National population register (one 
control per case; n=84 739). Control women were 
matched with cases by age (within 1 month) and by 
hospital district according to the woman’s municipality 
of residence. Hospital districts were further divided 
into five university hospital districts.
Finland has a reliable nationwide register that 
includes all hormone therapy users from year 1994. 
Use of the treatment in Finland is available only 
with a physician’s prescription, and regimens are 
partly (40-60%) reimbursed by the government. At 
each pharmacy visit, hormone therapy purchases 
are entered into the drug reimbursement register, 
confirming use of the prescribed regimen of hormone 
therapy. The register was initiated in 1994, so we could 
not differentiate whether a woman who bought the 
treatment in 1994 was a new user or was continuing 
her treatment initiated before 1994. Therefore, we 
assumed that all systemic users older than 52 years in 
1994 had initiated the treatment at age 52 and vaginal 
users at age 65, which are the mean ages at systemic 
and vaginal initiation of hormone therapy in our study 
population, respectively.18 This approximation has 
been used in several previous studies. 19-21 However, 
we also analysed separately women who had started 
hormone therapy in 1995 (one year after the register 
opened) or later (that is, fresh starters: 65 102 cases 
and 65 102 controls), because this group’s detailed 
history of treatment use was documented in the 
register. The findings in this subanalysis were fully in 
line with those in the whole study population, so the 
data of this subanalysis are not shown.
The regimens of systemic hormone therapy in 
Finland contain exclusively estradiol, which is given 
either orally (90%) or transdermally (10%). The 
regimens identified by trade names were transformed 
into doses of estradiol (oral or transdermal). Various 
progestogens were used in combination with estradiol 
(that is, oestrogen-progestogen therapy), of which 
norethisterone acetate and medroxyprogesterone 
acetate were the most common.20 According to the 
Finnish guidelines, only women who have had 
hysterectomies can use estradiol without progestogen, 
and these women were studied as an estradiol only 
group. Oral estradiol doses in Finland are usually 1-2 
mg/day, and transdermal (gel or patch) estradiol is 
used with equivalent doses (25-100 μg/day). However, 
owing to the switching of the use of hormone therapy 
from one route to another and to the relatively similar 
route independent levels of circulating oestrogen, we 
did no subanalyses according to the treatment route. 
Sequential users of oestrogen-progestogen therapy 
were defined as women who used estradiol with 10-
14 days of progestogen courses each month, or at 
intervals of one to three months. Women who used both 
estradiol and progestogen every day were considered 
as continuous users of oestrogen-progestogen therapy. 
Tibolone users were considered as a separate group. 
Users of vaginal estradiol only (Vagifem, NovoNordisk, 
Copenhagen, Denmark; 25 μg twice a week) were 
analysed separately.
Exposure to hormone therapy (ever use) was 
considered to have started from the date of the 
first purchase, or from age 52 if systemic hormone 
therapy was used at the register opening or from 
age 65 years if vaginal estradiol was used at register 
opening. Cumulative exposure to hormone therapy 
was classified by duration (lasting ≤3 years, >3 to ≤5 
years, >5 to ≤10 years, or >10 years). We assessed the 
time period from treatment initiation to diagnosis for 
Alzheimer’s disease. To address the potential critical 
time window for oestrogen brain effect,16 we also 
compared the risk of the disease in women who had 
started hormone therapy aged under 60 versus those 
aged 60 and over.
Statistical methods
We used a conditional logistic regression analysis to 
estimate, by using odds ratios with 95% confidence 
intervals, the relative risk of Alzheimer’s disease 
associated with different regimens of hormone therapy. 
The association between age at treatment initiation 
and Alzheimer’s disease was also analysed with 
conditional logistic regression, using both continuous 
age and five years age classes as variables. We used 
the χ2 test to test differences between categorical 
variables. Differences between continuous variables 
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were evaluated with the student’s t test or two tailed 
test of equal or given proportions. Significance was set 
at P<0.05.
Patient and public involvement
No patients were involved in the setting of the 
research question or the outcome measures, nor were 
they involved in the developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of the results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
Overall, in 83 688 (98.8%) women, a diagnosis for 
Alzheimer’s disease was made at the age of 60 years 
or older, and 47 239 (55.7%) women had been over 80 
years of age at diagnosis (table 1). Time from initiation 
of hormone therapy to diagnosis was shorter than five 
years in 886 (5.6%) women, but longer than 10 years 
in 11 805 (74.9%). At the time of diagnosis, only 2305 
(14.6%) women were still using hormone therapy, 
whereas 10 188 (64.6%) had stopped treatment more 
than three years before diagnosis. 
Patients with Alzheimer’s disease used systemic 
hormone therapy more often (18.6% v 17.0%, 
respectively, P<0.001) but used vaginal estradiol only 
less often (12.7% v 13.2%, P=0.005) than controls (table 
1). The mean exposure time to systemic hormone therapy 
did not differ between patients with Alzheimer’s disease 
and control women (table 1). The relative proportions of 
different progestogens users were similar in cases and 
controls (table 1), but exposure to oestrogen-progestogen 
therapy with other or mixed progestogens was longer in 
patients with Alzheimer’s disease (P=0.02).
Overall, hormone therapy users with Alzheimer’s 
disease (n=11 456, 73.7%) had started systemic 
hormone therapy under age 60 years less often than 
controls (n=10 662, 75.1%, P=0.006). The mean age 
at initiation of estradiol only was similar for patients 
with Alzheimer’s disease and controls (table 1), but 
the mean age at initiation of oestrogen-progestogen 
therapy was slightly higher for patients with 
Alzheimer’s disease than for controls (56.1 (standard 
deviation 7.8) v 55.8 (7.6), P=0.02).
Table 1 | Characteristics of study population. Data are number (%) of women unless stated otherwise
Patients with Alzheimer’s disease (n=84 739) Controls (n=84 739) P
Start of follow-up (age at Alzheimer diagnosis (years) for cases)
<50 99 (0.1) 101 (0.1) — 
50-54 273 (0.3) 274 (0.3) —
55-59 679 (0.8) 678 (0.8) —
60-64 1373 (1.6) 1373 (1.6) —
65-69 4028 (4.8) 4028 (4.7) —
70-74 10 731 (12.7) 10 785 (12.7) —
75-79 20 317 (24.0) 20 311 (24.0) —
≥80 47 239 (55.7) 47 193 (55.7) —
University healthcare district at the time of diagnosis
Northern (Oulu) 14 794 (17.5) 14 746 (17.4) —
Eastern (Kuopio) 17 425 (20.6) 17 450 (20.6) —
Southern (Helsinki) 24 053 (28.4) 23 956 (28.3) —
Western (Turku) 10 856 (12.8) 10 873 (12.8) —
Central Finland (Tampere) 17 574 (20.7) 17 624 (20.8) —
Unknown 6 (0.01) 3 (0.0) —
Abroad 31 (0.04) 87 (0.1) —
Hormone therapy use
No use 58 186 (68.7) 59 175 (69.8) <0.001
Systemic use 15 768 (18.6) 14 394 (17.0)
Estradiol only 5606 (35.6) 5312 (36.9) 0.01
EPT 9941 (63.0) 8890 (61.9)
 EPT with MPA 1955 (19.7) 1795 (20.1) 0.27
 EPT with NETA 3080 (31.0) 2661 (29.8)
 EPT with other* or mixed progestogens 4906 (49.4) 4434 (50.0)
Tibolone 221 (1.4) 192 (1.3) 0.17
Vaginal estradiol 10 785 (12.7) 11 170 (13.2) 0.005
Age at hormone therapy initiation (mean, SD)
Estradiol only 58.0 (9.3) 57.7 (9.0) 0.1
EPT 56.1 (7.8) 55.8 (7.6) 0.02
Exposure time (mean, SD)
Systemic use 11.4 (8.6) 11.5 (8.6) 0.19
Estradiol only 11.8 (9.3) 11.9 (9.4) 0.40
EPT 9.8 (7.7) 9.7 (7.7) 0.28
 EPT with MPA 9.6 (7.9) 9.7 (7.7) 0.10
 EPT with NETA 7.0 (7.4) 6.7 (7.3) 0.28
 EPT with other* or mixed progestogens 11.6 (7.4) 11.3 (7.4) 0.02
Tibolone 1.6 (1.8) 1.6 (1.7) 0.93
EPT=oestrogen-progestogen therapy; NETA=norethisterone acetate; MPA=medroxyprogesterone acetate; SD=standard deviation.
*Other progestogens include levonorgestrel, progesterone, megestrol acetate, lynestrenol, drospirenone, and trimegestone.
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In the whole study population, the risk of Alzheimer’s 
disease was increased but did not differ significantly 
between users of estradiol only (odds ratio 1.09, 95% 
confidence interval 1.05 to 1.14) and those of oestrogen-
progestogen (1.17, 1.13 to 1.21). Exclusive use of 
vaginal estradiol was not related to risk of Alzheimer’s 
disease (0.99, 0.96 to 1.01). In women younger than 
60 at hormone therapy initiation, use of the different 
oestrogen-progestogen therapies was associated with 
an 8-17% increased risk of Alzheimer’s disease (table 
2). We saw no significant differences between the 
different therapies with regards to Alzheimer’s disease 
risk. Use of estradiol only was associated with a small 
but significant increase in disease risk. The risk of 
Alzheimer’s disease in estradiol only users (odds ratio 
1.06, 95% confidence interval 1.01 to 1.12) and all 
users of oestrogen-progestogen therapy (1.14, 1.09 to 
1.19) did not differ significantly. The use of tibolone 
carried no significant risk of Alzheimer’s disease in 
this age group. The risk increases in users of estradiol 
only and oestrogen-progestogen therapy were related 
to 10 years of exposure or more, whereas shorter use of 
hormone therapy was not associated with Alzheimer’s 
disease risk (table 3).
In women aged 60 or older at the initiation of 
hormone therapy, use of estradiol only, oestrogen-
progestogen therapy, or tibolone was associated with 
similar increases in risk (15-38%) for Alzheimer’s 
Table 2 | Odds ratios for Alzheimer’s disease in women younger than 60 or aged 60 and older at treatment initiation of 
estradiol only or various combined therapies
Age at initiation and type of hormone therapy Patients with Alzheimer’s disease (No) Controls (No) Odds ratio (95% CI) P
Age <60 years
No hormone therapy 48 331 48 925 1.00 —
Estradiol only 3125 3042 1.06 (1.01 to 1.12) 0.03
EPT 6330 5812 1.14 (1.09 to 1.19) <0.005
 EPT with MPA 1296 1247 1.08 (1.00 to 1.17) 0.06
 EPT with NETA 1419 1270 1.17 (1.08 to 1.26) <0.005
 EPT with other* or mixed progestogens 3615 3295 1.15 (1.09 to 1.21) <0.005
Tibolone 83 90 0.97 (0.72 to 1.32) 0.86
Age ≥60 years
No hormone therapy 45 180 45 635 1.00 — 
Estradiol only 1310 1157 1.15 (1.06 to 1.25) <0.005
EPT 1630 1352 1.23 (1.14 to 1.32) <0.005
 EPT with MPA 269 227 1.21 (1.01 to 1.44) 0.04
 EPT with NETA 963 792 1.23 (1.12 to 1.36) <0.005
 EPT with other* or mixed progestogens 398 333 1.21 (1.05 to 1.41) 0.009
Tibolone 90 66 1.38 (1.00 to 1.89) 0.05
EPT=oestrogen-progestogen therapy; NETA=norethisterone acetate; MPA=medroxyprogesterone acetate.
*Other progestogens include levonorgestrel, progesterone, megestrol acetate, lynestrenol, drospirenone, and trimegestone.
Table 3 | Odds ratios for Alzheimer’s disease in women younger than 60 or aged 60 and over at treatment initiation of 
estradiol only or various combined therapies, stratified by duration of treatment
Type and duration of hormone therapy Patients with Alzheimer’s disease (No) Controls (No) Odds ratio (95% CI) P
Age <60 years at treatment initiation
Estradiol only 
 No hormone therapy 44 879 44 978 1.00 —
 <3 years 126 140 0.89 (0.69 to 1.15) 0.38
 3 to <5 years 78 60 1.31 (0.93 to 1.87) 0.13
 5 to <10 years 254 286 0.88 (0.74 to 1.06) 0.18
 ≥10 years 1989 1862 1.07 (1.00 to 1.15) 0.04
Oestrogen-progestogen therapy 
 No hormone therapy 46 301 46 796 1.00 —
 <3 years 845 854 1.02 (0.92 to 1.13) 0.67
 3 to <5 years 401 416 1.00 (0.86 to 1.15) 0.98
 5 to <10 years 1118 1063 1.10 (1.00 to 1.20) 0.05
 ≥10 years 3355 2891 1.20 (1.13 to 1.26) <0.005
Age ≥60 years at treatment initiation
Estradiol only 
 No hormone therapy 43 894 44 062 1.00 —
 <3 years 905 804 1.13 (1.03 to 1.25) 0.01
 3 to <5 years 160 119 1.35 (1.07 to 1.72) 0.01
 5 to <10 years 164 139 1.19 (0.95 to 1.50) 0.13
 ≥10 years 28 27 1.04 (0.61 to 1.77) 0.88
Oestrogen-progestogen therapy 
 No hormone therapy 44 135 44 422 1.00 —
 <3 years 1204 1015 1.20 (1.10 to 1.30) <0.005
 3 to <5 years 233 179 1.32 (1.08 to 1.60) 0.006
 5 to <10 years 198 147 1.36 (1.10 to 1.69) <0.005
 ≥10 years 17 24 0.73 (0.39 to 1.35) 0.31
 on 4 A










J: first published as 10.1136/bm






the bmj | BMJ 2019;364:l665 | doi: 10.1136/bmj.l665 5
disease (table 2). In this age group, the increased risk 
was already detectable after three to five years’ use 
of estradiol only or oestrogen-progestogen therapy 
(table 3). The increases in risk of Alzheimer’s disease 
between women younger than 60 and those aged 60 or 
older at treatment initiation did not differ significantly. 
When the effect of age at treatment initiation on 
risk of Alzheimer’s disease was analysed further in 
five year intervals, no association emerged (fig 1). 
Furthermore, age as a continuous variable was no 
determinant for disease risk in users of estradiol only 
(odds ratio 1.0, 95% confidence interval 0.98 to 1.02), 
oestrogen-progestogen therapy (1.0, 0.99 to 1.01), or 
any hormone therapy (1.0, 0.99 to 1.01). The disease 
appeared earlier in women with a history of systemic 
use of hormone therapy than in those with vaginal 




In our large case-control study of 84 739 patients with 
Alzheimer’s disease and a similar number of control 
women, we showed that the systemic use of estradiol 
only or oestrogen-progestogen therapy was associated 
with an increased risk of Alzheimer’s disease, whereas 
use of vaginal estradiol showed no such risk. The age 
at initiation of hormone therapy did not appear to be a 
determinant for risk of the disease, whereas in women 
younger than 60 at treatment initiation, the risk 
increases were associated with exposure to hormone 
therapy for over 10 years.
Comparison with other studies
Most observational studies have reported a reduced 
risk of Alzheimer’s disease and all cause dementia in 
users of hormone therapy.8-13 22 These analyses can be 
criticised, owing to the lack of a placebo arm and the 
possible bias of healthy woman in hormone therapy 
users. This criticism gained strong support from the 
placebo controlled WHIMS trial, reporting an increased 
risk of impaired cognition and probable dementia in 
women who used conjugated equine oestrogens (CEE) 
with and without medroxyprogesterone acetate.14  15 
On the other hand, this study was also criticised 
because, unlike in normal clinical practice, hormone 
therapy was initiated for women older than 65, many 
years after the onset of menopause. Moreover, the 
WHIMS study did not differentiate Alzheimer’s disease 
from other dementia or cognitive decline, although 
the pathophysiology of dementia includes multiple 
different neurodegenerative and vascular processes, 
which could respond differently to oestrogen exposure.
Our epidemiological study, although large in size 
and conducted in a case-control setting, can show 
only associations between hormone therapy use and 
the risk of Alzheimer’s disease. Moreover, the small 
risk increases are vulnerable to bias from unsuspected 
sources, which are unavoidable in all observational 
studies.8-13 But if there is a causal relation, it seems 
that estradiol could be primarily responsible for the 
increased risk of Alzheimer’s disease, because use 
of estradiol only was related to the increased risk. 
However, progestogen could potentiate the effect of 
estradiol on the risk of Alzheimer’s disease, because the 
risk elevations tended to be higher in users of oestrogen-
progestogen therapy than users of estradiol only. This 
notion accords with the WHIMS study finding14 15 that 
the risk of all cause dementia was higher in users of CEE 
and medroxyprogesterone acetate than in those using 
CEE only. Progestogens, such as medroxyprogesterone 
acetate or norethisterone acetate, differ in structure 
and in their capacity to bind to progesterone and other 
steroid hormone receptors23; therefore, the risk of 
Alzheimer’s disease in users of the different oestrogen-
progestogen therapies could vary. Our data show 
that norethisterone acetate, medroxyprogesterone 
acetate, or other progestogens as components of 
oestrogen-progestogen therapy do not differ in regard 
to risk of Alzheimer’s disease. Tibolone, a synthetic 
steroid hormone with oestrogenic, progestogenic, 
and androgenic actions, has shown a neuroprotective 
effect in preclinical studies.24 Our finding implies that 
tibolone does not differentiate significantly from other 
forms of systemic hormone therapy with regard to the 
risk of Alzheimer’s disease, but owing to the small 
number of tibolone users, this conclusion must be 
interpreted with caution.
The cause of Alzheimer’s disease is not yet fully 
understood, but β amyloid plaques and neurofibrillary 
tangles containing hyperphosphorylated τ protein 
do accumulate in the brain. 25 26 Several risk factors, 
such as genetic tendency, head trauma, smoking, and 
low education could speed up the development of the 
disease. Multiple full term pregnancies might also 
predispose to the development of Alzheimer’s disease, 
perhaps due to repeat oestrogen and progesterone 
surges.27 Our present data imply that the prolongation 
of estradiol exposure beyond the natural menopausal 
age with the use of hormone therapy could stimulate 
the progression of Alzheimer’s disease, and thus 
increase its risk, especially if such exposure to estradiol 
is continued for over 10 years. Our data do not allow 





















Fig 1 | Risk of Alzheimer’s disease in women initiating systemic hormone therapy (HT) at 
different ages, as odds ratios and 95% confidence intervals. Line at 1.0 denotes the risk 
in the group of women who started systemic use younger than 55. Numbers of cases 
and controls are given for five years periods
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mechanism through which estradiol could have 
caused this effect. Although estradiol might inhibit 
the accumulation of β amyloid in animal models and 
in early postmenopausal women,3 6 28 it has been 
speculated that such an effect of oestrogen is lost 
with advancing age. We sought thoroughly for such a 
timing effect from our data, but we must conclude that 
the age at initiation of hormone therapy is no decisive 
determinant for the risk of Alzheimer’s disease in the 
future.
We have previously shown that the systemic use of 
estradiol based hormone therapy was associated with 
a marked difference in the death risk of dementia; the 
risk of death for vascular dementia was profoundly 
decreased (by 37-39%), whereas risk of death 
for Alzheimer’s disease showed a much smaller 
decrease or even lacked a decrease. 21 Furthermore, 
in the extended follow-up of the Women’s Health 
Initiative study,29 the mortality for Alzheimer’s 
disease and other dementia was reduced in CEE 
users, although the authors conclude that this finding 
should be interpreted cautiously because of multiple 
comparisons. It is possible that the use of hormone 
therapy is accompanied, directly or indirectly, with a 
decreased risk of the most severe forms of Alzheimer’s 
disease, perhaps by improving cardiovascular health. 
Yet, it is the incidence of and not mortality from 
Alzheimer’s disease that determines the total burden 
of the disease.
Strengths and limitations of the study
Our study had several limitations. Firstly, we did 
not have baseline demographic data for known risk 
factors for Alzheimer’s disease, either for the hormone 
therapy users or controls. We would not expect this 
omission to cause many errors in our study, because 
several common dementia risk factors (hypertension, 
hypercholesterolaemia, and smoking) were evenly 
distributed between the two groups in another study 
from the same population.30 Moreover, cardiovascular 
mortality was reduced in the Finnish hormone 
therapy users,18 20 implying that higher cardiovascular 
morbidity could not explain the elevated disease risk 
of hormone therapy users in our study. The ApoE 
E4 allele frequency in Finland (at nearly 20%) is 
among the highest in the world,31 32 and some studies 
suggest that the effects of postmenopausal hormone 
therapy on Alzheimer’s disease are modified by the 
ApoE status.2 ApoE E4 is not screened in the Finnish 
healthcare system, but it is unlikely that ApoE status 
would have differed between the two study groups. 
Furthermore, Finnish users of hormone therapy did 
not differ in socioeconomic status or education from 
the non-users,33 and healthcare services in Finland are 
available for everyone, free of charge, or substantially 
subsidised. 
Secondly, due to the first signs of cognitive 
impairment seven to eight years before the final 
diagnosis,34 there is a possibility that such women 
sought help from hormone therapy, and thus an 
increased risk of Alzheimer’s disease was a cause 
for its use and not its consequence. However, this 
seems unlikely in our population, because the disease 
diagnosed most often at over age 80 would have 
caused symptoms at around age 72-7334; however, 
most hormone therapy users (74%) started use under 
age 60. Furthermore, only 14% of users were still on 
hormone therapy at the time of diagnosis. Thirdly, 
the duration of the pre-register use of hormone 
therapy had to be estimated in a quarter of the total 
study population. However, based on the previous 
data,20 21 such an estimation for hormone therapy 
use is accurate. Fourthly, controls were not screened 
with magnetic resonance imaging of the brain or 
neurological examination to exclude Alzheimer’s 
disease, and thus some controls could have had 
undiagnosed disease. This chance should not cause 
any concern because the prevalence of Alzheimer’s 
disease in Europe is 4.4%.35 Finally, although we 
could reliably differentiate between systemic and 
vaginal use of estradiol, we were not able to compare 
the use of oral and transdermal preparations with 
use of cyclic and continuous oestrogen-progestogen 
therapy.
Our study also had several strengths. Firstly, this 
study is one of the largest on the association between 
hormone therapy and Alzheimer’s disease. Secondly, 
it is vital that in a study on women with cognitive 
decline, the use of hormone therapy was objectively 
assessed from a reliable nationwide register controlled 
by authorities, because self reporting is not reliable 
in patients with poor cognitive performance. Thirdly, 
Alzheimer’s disease was accurately diagnosed and 
differentiated from vascular dementia and other 
forms of dementia or cognitive decline according to 
internationally approved criteria.36 Finally, it has been 
shown that 97% of Finnish patients with Alzheimer’s 
disease actually use treatment37 and thus have been 
included into the reimbursement register, which 
confirms that we could reliably detect patients with 
Alzheimer’s disease in Finland.
Conclusions and policy implications
The present study indicates that the use of systemic 





































































Vaginal use of estradiol
Fig 2 | Proportion (%) of women with a diagnosis of Alzheimer’s disease in different 
age groups according to systemic use of hormone therapy, vaginal use of estradiol, or 
without any history of hormone therapy (HT) use
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Alzheimer’s disease, is accompanied with a 9-17% 
increase in the risk of the disease in postmenopausal 
women, whereas the exclusive use of vaginal estradiol 
shows no risk. In absolute terms, we estimate that nine 
to 18 excess diagnoses of the disease per year will be 
detected in 10 000 women aged 70-80 (incidence 105 
per 10 000 women years in this age group), especially 
in those who had used hormone therapy for over 10 
years. The age at initiation of hormone therapy is no 
decisive determinant for the future risk of Alzheimer’s 
disease. Hormone therapy users should be informed of 
a possible risk of the disease with prolonged use, even 
though the absolute risk elevations are small.
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